A previous GWAS linked IRX1 with brain parenchymal volume in MS but did not reach genome-wide significance and reported no effect on disability.3 This may be due to shorter disease duration (range 10.7–12.9 years). The gene discussed is IRX1; the disease is myeloid sarcoma.